8-K: Fate Therapeutics Treats First Lupus Patient with FT819, Presents Promising Data at ASGCT

Fate Therapeutics has dosed the first patient in its Phase 1 autoimmunity study of FT819 and presented encouraging translational data for both its FT819 and FT522 programs at the ASGCT annual meeting.

Summary

• Fate Therapeutics announced the treatment of the first patient with systemic lupus erythematosus (SLE) in a Phase 1 study of FT819, an off-the-shelf CAR T-cell therapy.
• The company also presented translational data at the ASGCT annual meeting for FT819 in B-cell malignancies (BCM) and FT522 in B-cell lymphoma (BCL).
• FT819 showed multiple therapeutic mechanisms for generating an immune reset in B cell-mediated autoimmune disease.
• In the BCM study, 43 heavily pre-treated patients received a single dose of FT819, with a favorable safety profile up to 1.08 billion cells.
• Clinical responses were observed across different B-cell cancer types, with a 47% overall response rate and 24% complete response rate in 17 patients with aggressive large B-cell lymphoma.
• FT522, a CAR NK cell therapy, demonstrated rapid, deep, and sustained B-cell depletion in the first two patients treated in its BCL study.
• FT522 also showed enhanced persistence compared to a prior-generation CAR NK cell therapy, FT596.
• Fate Therapeutics plans to submit an IND application for FT522 in autoimmune diseases in mid-2024.

Sentiment

Score: 8

Explanation: The document presents positive clinical data and progress in both the FT819 and FT522 programs, with a clear path forward for the company's autoimmune pipeline. The sentiment is optimistic, with a focus on the potential of the iPSC platform.

Positives

• The first patient with SLE was treated with FT819, marking a significant step in the autoimmune program.
• FT819 demonstrated a favorable safety profile in the BCM study, with no serious adverse events.
• Clinical responses were observed across different B-cell cancer types in the FT819 BCM study.
• FT522 showed promising early results with rapid and sustained B-cell depletion and enhanced persistence.
• The company is advancing its iPSC platform for both cancer and autoimmune diseases.

Negatives

• The document does not explicitly mention any negative results, but it does highlight the risks associated with clinical trials and product development.
• The document notes that the company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons.

Risks

• The company's research and development programs and product candidates may not demonstrate the required safety or efficacy.
• Results observed in prior studies may not be replicated in ongoing or future studies.
• There is a risk of delays or difficulties in manufacturing the company's product candidates.
• The company may face challenges in initiating, conducting, or enrolling patients in clinical trials.
• The company's product candidates may not produce therapeutic benefits or may cause unanticipated adverse effects.

Future Outlook

Fate Therapeutics plans to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the middle of 2024 for the treatment of various autoimmune diseases with FT522.

Management Comments

• Jennifer Medlin, M.D., stated that off-the-shelf cell products like FT819 may overcome challenges limiting patient access to CAR-T for autoimmune diseases.
• Scott Wolchko, President and CEO of Fate Therapeutics, expressed excitement about bringing their iPSC platform to patients with autoimmune diseases.

Industry Context

This announcement highlights the growing interest in off-the-shelf cell therapies for both cancer and autoimmune diseases, with Fate Therapeutics positioning itself as a leader in iPSC-derived cell therapies. The data presented at ASGCT contributes to the broader understanding of CAR T-cell and CAR NK cell mechanisms and their potential in these therapeutic areas.

Comparison to Industry Standards

• The 47% overall response rate and 24% complete response rate in relapsed/refractory aggressive large B-cell lymphoma with FT819 is comparable to some autologous CAR T-cell therapies, but the key advantage is the off-the-shelf nature of FT819.
• The enhanced persistence of FT522 compared to FT596 suggests an improvement in CAR NK cell technology, addressing a common challenge in the field.
• The ability of FT522 to function effectively in the presence of an unmatched host immune system, as demonstrated in the re-challenge assay, is a significant advancement over traditional cell therapies.
• The company's focus on iPSC-derived therapies positions them against companies using donor-derived cells, such as Kite Pharma and Novartis, who are leaders in autologous CAR-T therapies.

Stakeholder Impact

• Shareholders may view the positive clinical data and progress as favorable.
• Patients with autoimmune diseases may benefit from the development of new treatment options.
• Employees may be motivated by the company's progress and potential impact on patients.

Next Steps

• Fate Therapeutics intends to submit an IND application for FT522 in autoimmune diseases in mid-2024.
• The company will continue to enroll patients in the Phase 1 autoimmunity study of FT819.
• The company will continue to develop and advance its iPSC-derived cell therapy platform.

Key Dates

Keywords

CAR T-cell therapy, CAR NK cell therapy, iPSC, FT819, FT522, Autoimmune disease, Systemic lupus erythematosus, B-cell lymphoma, B-cell malignancies, Cellular immunotherapy